Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sodium-Glucose Transporter 2 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT05345327
What this trial is testing

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Who this might be right for
Type 2 Diabetes
The George Institute 994
Post-approval studies (Phase 4)Not Yet RecruitingNCT07537088
What this trial is testing

Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

Who this might be right for
T2DM (Type 2 Diabetes Mellitus)CKD - Chronic Kidney Disease
First Affiliated Hospital of Wannan Medical College 468
Post-approval studies (Phase 4)Study completedNCT02847091
What this trial is testing

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

Who this might be right for
Type 2 Diabetes Mellitus
Astellas Pharma Inc 103
Early research (Phase 1)Looking for participantsNCT05521984
What this trial is testing

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Who this might be right for
Pediatric Brain TumorPediatric Solid Tumor
Washington University School of Medicine 20
Early research (Phase 1)Study completedNCT01512849
What this trial is testing

Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Who this might be right for
Type 2 Diabetes Mellitus
Tanabe Pharma Corporation 24
Early research (Phase 1)Study completedNCT00836225
What this trial is testing

Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

Who this might be right for
Type 2 Diabetes Mellitus
Ionis Pharmaceuticals, Inc. 103
Not applicableActive Not RecruitingNCT06901609
What this trial is testing

Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients

Who this might be right for
Heart Failure - NYHA II - IVCardiac FibrosisCardiac Remodeling
Ain Shams University 200
Large-scale testing (Phase 3)Looking for participantsNCT05852704
What this trial is testing

SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF

Who this might be right for
Chronic Coronary SyndromeAtrial Fibrillation
Region Örebro County 800
Post-approval studies (Phase 4)Looking for participantsNCT06055452
What this trial is testing

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Who this might be right for
Pre-Heart FailureHypertension
China National Center for Cardiovascular Diseases 120
Testing effectiveness (Phase 2)Looking for participantsNCT06762964
What this trial is testing

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

Who this might be right for
Fontan CirculationSingle Ventricle Heart DiseaseHFpEF - Heart Failure With Preserved Ejection Fraction
Mayo Clinic 27
Post-approval studies (Phase 4)Study completedNCT04447911
What this trial is testing

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

Who this might be right for
HyponatremiaSIADHLiver Failure+1 more
University Hospital, Basel, Switzerland 113
Post-approval studies (Phase 4)WithdrawnNCT02768220
What this trial is testing

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Who this might be right for
SGLT-2 InhibitorsAdvanced Glycation End ProductsDiabetes
Northwell Health
Not applicableNot Yet RecruitingNCT07355088
What this trial is testing

Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study

Who this might be right for
Chronic Heart FailureHeart Failure With Reduced Ejection Fraction (HFrEF)Heart Failure With Preserved Ejection Fraction (HFPEF)+1 more
Xinjiang Medical University 600
Testing effectiveness (Phase 2)Looking for participantsNCT06887062
What this trial is testing

Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

Who this might be right for
Large Vessel VasculitisGiant Cell Arteritis (GCA)Takayasu Arteritis
University of Edinburgh 60
Post-approval studies (Phase 4)Ended earlyNCT05346653
What this trial is testing

The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

Who this might be right for
Acute Decompensated Heart Failure
University of Chicago 1
Testing effectiveness (Phase 2)Study completedNCT03556033
What this trial is testing

Effect of Dapagliflozin on IAH in T1DM

Who this might be right for
Diabetes Mellitus, Type 1HypoglycemiaHypoglycemia Unawareness
Radboud University Medical Center 15
Not applicableUnknownNCT06344247
What this trial is testing

Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Who this might be right for
ObesityChronic Kidney Diseases
RenJi Hospital 48
Large-scale testing (Phase 3)Study completedNCT02874807
What this trial is testing

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

Who this might be right for
SIADH
University Hospital, Basel, Switzerland 88
Large-scale testing (Phase 3)Study completedNCT02787551
What this trial is testing

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Who this might be right for
Type 2 Diabetes Mellitus
Sanofi 514
Post-approval studies (Phase 4)UnknownNCT03398577
What this trial is testing

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Who this might be right for
Coronary Disease With Diabetes Mellitus
Sheba Medical Center 61
Next Page